Inhibition of epigenetic control enzymes in immune cells as a potential new starting point in cancer immunotherapy

Inhibition of epigenetic control enzymes in immune cells as a potential new starting point in cancer immunotherapy." ScienceDaily. ScienceDaily, 7 June 2024. <www.sciencedaily.comMedical University of Vienna. . Inhibition of epigenetic control enzymes in immune cells as a potential new starting point in cancer immunotherapy.Medical University of Vienna."Inhibition of epigenetic control enzymes in immune cells as a potential new starting point in cancer immunotherapy.

Scientists discovered that anti-CTLA-4 immunotherapy extended the lives of mice with glioblastoma by causing specialized CD4+ T immune cells to 1) infiltrate the brain and 2) tell brain-resident ... Researchers have demonstrated a promising new approach to delivering immunotherapy agents to fight cancer. The approach involves tethering an immunotherapy agent called a STING agonist to an ...

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn't work, and new research may help explain why. When immune cells called T ... Researchers have discovered lymph node-like structures close to the tumor in brain cancer patients, where immune cells can be activated to attack the tumor. They also found that immunotherapy ...People Feel More Connected to 'Tweezer-Like' Bionic Tools That Don't Resemble Human HandsBrain Waves Shape the Words We Hear

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Research finds VISTA directly blocks T-cells from functioning in immunotherapyA team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The study explains that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote bone and fat development.
Source: ScienceDaily - 🏆 452. / 53 Read more »

Circadian clock can be leveraged to enhance cancer immunotherapyA multidisciplinary research team has revealed that the circadian clock -- the biological pacemaker that governs daily rhythms in physiological processes, including immune functions -- can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
Source: ScienceDaily - 🏆 452. / 53 Read more »

Immunotherapy Before and After Surgery Boosts Lung Cancer SurvivalImmunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it’s combined with chemotherapy, a new clinical trial reports.
Source: MedicineNet - 🏆 575. / 51 Read more »

Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancerCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy -- given before and after surgery -- significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers.
Source: ScienceDaily - 🏆 452. / 53 Read more »